LadRx (STU:CX5) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CX5 LadRx Corp STU:CX5
40 GF Score
Price €0.06
View Full Analysis

What is LadRx 5-Year Yield-on-Cost %?

LadRx STU:CX5 40 5-Year Yield-on-Cost % is 0.00 as of Aug. 10, 2026. GuruFocus rates STU:CX5 with a GF Score™ of 40/100.

LadRx's yield on cost for the quarter that ended in Mar. 2025 was 0.00.


The historical rank and industry rank for LadRx's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:CX5's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

LadRx  (STU:CX5) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

LadRx 5-Year Yield-on-Cost % Related Terms

STU:CX5 vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, LadRx's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LadRx 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where LadRx's 5-Year Yield-on-Cost % falls into.


STU:CX5
40GF Score
LadRx Corp STU:CX5
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LadRx 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of LadRx is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
LadRx (STU:CX5) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 10, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on LadRx and its competitors.
Is LadRx's 5-Year Yield-on-Cost % too high?
LadRx's current 5-Year Yield-on-Cost % is 0.00. Overall, LadRx has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does LadRx's 5-Year Yield-on-Cost % compare to VRTX and REGN?
LadRx's 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Biotechnology industry. The industry median 5-Year Yield-on-Cost % is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on LadRx and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LadRx's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LadRx stock overvalued right now?
LadRx (STU:CX5) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. LadRx's overall GF Score™ is 40/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For LadRx (STU:CX5), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LadRx Business Description

Address 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
40GF Score

Get the complete analysis for STU:CX5

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price